Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP vaccine is a combination immunizing agent used to prevent diphtheria, tetanus (lockjaw), and pertussis (whooping cough) in children. It contains inactivated toxins and bacterial components that help the body develop immunity against these potentially life-threatening diseases. The vaccine is administered as a five-dose series in children between 6 weeks and 6 years of age (before the child's 7th birthday).
- Brand names
- DaptacelInfanrix
- Other names
- DTaP Vaccine ADTaP
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria, tetanus, acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, acellular pertussis vaccine.